GSK plc (GSK)

Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending

GSK has been impressing me with strong revenue and EPS numbers for the eighth quarter in a row. Also, on December 12, depemokimab, GSK's anti-IL-5 antibody with 6-month dosing, received a positive EMA's CHMP opinion for the treatment of certain patients with severe asthma and CRSwNP. And yesterday, the FDA approved Blujepa for the treatment of uncomplicated urogenital gonorrhea.

Analysts are increasingly focusing on GSK (GSK) after Europe's drug regulator delivered what could be a pivotal endorsement for depemokimab, a treatment positio

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments.

GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.

The U.S. Food and Drug Administration on Thursday approved GSK's oral treatment for gonorrhea, a sexually transmitted infection.

GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.

GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug Administration granted the treatment Orphan Drug Designation for small-cell lung cancer. The company said the decision was supported by early data from its phase I ARTEMIS-001 study, where some patients with extensive-stage small-cell lung cancer, a form of the disease that has spread widely and is notoriously hard to treat, showed durable responses.

GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug...

Oxford, UK and San Jose, California , 10th December 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year, multi-target strategic collaboration with GSK to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in global pharma. The bank says a wave of clinical readouts (and a high likelihood of success) positions AstraZeneca to benefit disproportionately as investors shift their attention away from US drug-pricing fears and back towards innovation.

Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public health experts fear will undermine decades of public health advances.